A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis

Clin Exp Rheumatol. 2000 Nov-Dec;18(6):732-4.


Objective: To survey the effectiveness of etanercept in the treatment of severe, resistant psoriatic arthritis.

Methods: Ten patients coming from the clinical practice of 5 different rheumatologists and already using etanercept (25 mg subcutaneously twice weekly) were formally assessed at 3 and 12 months after etanercept use.

Results: All patients had improvement in their arthritis. Five of the 10 patients had no arthritis, 4 required only etanercept for disease control at 3 months. At 12 months, 8 of 10 patients were still on etanercept with continued good response. One patient had to discontinue etanercept due to osteomyelitis, and one due to increased disease activity. Of 4 patients with active skin disease, 3 had complete clearing. There were no side effects related to etanercept in this small, heterogeneously collected group of patients.

Conclusions: This preliminary and rather favorable experience with etanercept suggests that properly controlled trials of this agent in psoriatic arthritis are needed.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Psoriatic / drug therapy*
  • Arthritis, Psoriatic / physiopathology
  • Drug Resistance
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Retreatment
  • Severity of Illness Index
  • Treatment Outcome


  • Anti-Inflammatory Agents, Non-Steroidal
  • Antirheumatic Agents
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Receptors, Tumor Necrosis Factor
  • Etanercept